Administration of therapeutic- versus prophylactic-dose anticoagulation with heparins linked to lower mortality in patients hospitalized for COVID-19<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
THURSDAY, Dec. 26, 2024 (HealthDay News) — For patients hospitalized for COVID-19, administration of therapeutic-dose versus prophylactic-dose anticoagulation with heparins is associated with lower 28-day mortality, according to a review published online Dec. 24 in the Annals of Internal Medicine<\/em>.<\/p>\n Claire L. Vale, Ph.D., and colleagues from the World Health Organization Rapid Evidence Appraisal for COVID-19 Therapies Working Group, estimated the association of higher-dose versus lower-dose anticoagulation with clinical outcomes for patients hospitalized with COVID-19 using data from 20 eligible trials and two additional studies.<\/p>\n The researchers found that 28-day mortality was reduced with therapeutic-dose versus prophylactic-dose anticoagulation with heparins (odds ratio, 0.77; 95 percent confidence interval, 0.64 to 0.93; 11 trials included 6,297 patients, 5,456 of whom required low or no oxygen at randomization). For 28-day mortality, the odds ratios were 1.21 (95 percent confidence interval, 0.93 to 1.58) for therapeutic-dose versus intermediate-dose anticoagulation and 0.95 (95 percent confidence interval, 0.76 to 1.19) for intermediate- versus prophylactic-dose anticoagulation. Across predefined patient subgroups, treatment effects were broadly consistent; some analyses were limited in power. Fewer thromboembolic events were seen in association with higher- versus lower-dose anticoagulation, but the risk for major bleeding was greater.<\/p>\n “For each comparison, higher- compared with lower-dose anticoagulation was associated with fewer thromboembolic events but a greater risk for major bleeding,” the authors write.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n